Sarepta Therapeutics (SRPT) Retained Earnings (2016 - 2025)
Historic Retained Earnings for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to -$4.6 billion.
- Sarepta Therapeutics' Retained Earnings fell 621.31% to -$4.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.6 billion, marking a year-over-year decrease of 621.31%. This contributed to the annual value of -$4.2 billion for FY2024, which is 529.08% up from last year.
- Latest data reveals that Sarepta Therapeutics reported Retained Earnings of -$4.6 billion as of Q3 2025, which was down 621.31% from -$4.5 billion recorded in Q2 2025.
- In the past 5 years, Sarepta Therapeutics' Retained Earnings ranged from a high of -$3.0 billion in Q1 2021 and a low of -$4.7 billion during Q1 2025
- Over the past 5 years, Sarepta Therapeutics' median Retained Earnings value was -$4.4 billion (recorded in 2024), while the average stood at -$4.0 billion.
- In the last 5 years, Sarepta Therapeutics' Retained Earnings crashed by 3367.43% in 2023 and then skyrocketed by 529.08% in 2024.
- Quarter analysis of 5 years shows Sarepta Therapeutics' Retained Earnings stood at -$3.2 billion in 2021, then dropped by 21.94% to -$3.9 billion in 2022, then decreased by 13.71% to -$4.4 billion in 2023, then grew by 5.29% to -$4.2 billion in 2024, then decreased by 10.22% to -$4.6 billion in 2025.
- Its Retained Earnings stands at -$4.6 billion for Q3 2025, versus -$4.5 billion for Q2 2025 and -$4.7 billion for Q1 2025.